BR112015000229A2 - formulações aquosas estáveis de etanercept - Google Patents
formulações aquosas estáveis de etanerceptInfo
- Publication number
- BR112015000229A2 BR112015000229A2 BR112015000229A BR112015000229A BR112015000229A2 BR 112015000229 A2 BR112015000229 A2 BR 112015000229A2 BR 112015000229 A BR112015000229 A BR 112015000229A BR 112015000229 A BR112015000229 A BR 112015000229A BR 112015000229 A2 BR112015000229 A2 BR 112015000229A2
- Authority
- BR
- Brazil
- Prior art keywords
- etanercept
- stable aqueous
- aqueous formulations
- methods
- compositions
- Prior art date
Links
- 108010008165 Etanercept Proteins 0.000 title abstract 4
- 229960000403 etanercept Drugs 0.000 title abstract 4
- 239000013011 aqueous formulation Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000007774 longterm Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Abstract
resumo patente de invenção: "formulações aquosas estáveis de etanercept". a invenção refere-se a composições de etanercept farmacêuticas aquosas estabilizadas adequadas para armazenagem de longo prazo de etanercept, métodos de produção destas composições, métodos de administração, e kits contendo as mesmas.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261669480P | 2012-07-09 | 2012-07-09 | |
US201361806235P | 2013-03-28 | 2013-03-28 | |
PCT/US2013/049716 WO2014011629A1 (en) | 2012-07-09 | 2013-07-09 | Stable aqueous formulations of etanercept |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112015000229A2 true BR112015000229A2 (pt) | 2017-06-27 |
Family
ID=49916504
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015000203A BR112015000203A2 (pt) | 2012-07-09 | 2013-07-09 | formulações de etanercept que exibem redução marcada em partículas sub-visíveis |
BR112015000229A BR112015000229A2 (pt) | 2012-07-09 | 2013-07-09 | formulações aquosas estáveis de etanercept |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015000203A BR112015000203A2 (pt) | 2012-07-09 | 2013-07-09 | formulações de etanercept que exibem redução marcada em partículas sub-visíveis |
Country Status (19)
Country | Link |
---|---|
US (3) | US9662396B2 (pt) |
EP (2) | EP2869817A4 (pt) |
JP (2) | JP6271536B2 (pt) |
KR (1) | KR20150030704A (pt) |
CN (1) | CN104661651A (pt) |
AU (1) | AU2013290289B2 (pt) |
BR (2) | BR112015000203A2 (pt) |
CA (1) | CA2878508A1 (pt) |
CL (1) | CL2015000051A1 (pt) |
DO (1) | DOP2015000006A (pt) |
EA (1) | EA029193B1 (pt) |
EC (1) | ECSP15004752A (pt) |
HK (2) | HK1213174A1 (pt) |
IL (1) | IL236527A0 (pt) |
IN (1) | IN2015KN00005A (pt) |
MX (1) | MX2015000337A (pt) |
PE (1) | PE20150762A1 (pt) |
SG (1) | SG11201500138VA (pt) |
WO (2) | WO2014011672A1 (pt) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2776657T3 (es) | 2005-06-14 | 2020-07-31 | Amgen Inc | Formulaciones de proteínas autotamponantes |
CN104902914B (zh) * | 2012-09-11 | 2019-01-01 | 科荣生生物科学公司 | 高纯度和优异产量的正确折叠的依那西普 |
RU2663727C2 (ru) * | 2013-05-02 | 2018-08-08 | Мабксьенсе С.А. | Альтернативные составы для химерных полипептидов tnfr:fc |
HUE053654T2 (hu) | 2014-03-26 | 2021-07-28 | Astex Therapeutics Ltd | FGFR- és CMET-inhibitorok kombinációi a rák kezelésére |
US20180200325A1 (en) * | 2014-11-18 | 2018-07-19 | Shionogi & Co., Ltd. | Stabilized peptide composition |
JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
MX2015010517A (es) * | 2015-08-13 | 2017-02-13 | Landsteiner Scient S A De C V | Composicion de estabilidad mejorada de etanercept. |
WO2017159585A1 (ja) * | 2016-03-14 | 2017-09-21 | 参天製薬株式会社 | メグルミン又はその塩からなる防腐剤 |
MX2019004580A (es) * | 2016-10-21 | 2019-08-12 | Amgen Inc | Formulaciones farmaceuticas y metodos para prepararlas. |
WO2018094316A1 (en) * | 2016-11-21 | 2018-05-24 | Just Biotherapeutics, Inc. | Aflibercept formulations and uses thereof |
MX2017013995A (es) * | 2017-10-31 | 2019-05-01 | Probiomed S A De C V | Formulacion farmaceutica estable de una proteina de fusion. |
EP3710139A4 (en) * | 2017-11-13 | 2021-09-08 | Amgen Inc. | PROTEIN PRODUCTS PRODUCTION PROCESSES |
EP3781124A1 (en) * | 2018-04-16 | 2021-02-24 | Merck Patent GmbH | Method for stabilizing protein comprising formulations by using a meglumine salt |
JP7395504B2 (ja) * | 2018-04-24 | 2023-12-11 | アムジェン インコーポレイテッド | 注射可能医薬組成物の製造方法 |
CA3042126A1 (en) | 2018-05-03 | 2019-11-03 | Michael A. Portman | Methods of treating kawasaki disease |
TR201808283A2 (tr) * | 2018-06-11 | 2018-07-23 | Centurion Ilac San Ve Tic A S | Sulu farmasöti̇k etenersept bi̇leşi̇mi̇ |
GB201911461D0 (en) | 2019-08-09 | 2019-09-25 | Arecor Ltd | Novel composition |
WO2021083910A1 (en) * | 2019-10-28 | 2021-05-06 | Astrazeneca Ab | Dry powder formulations containing leucine and trileucine |
IL305010A (en) | 2021-02-17 | 2023-10-01 | Arecor Ltd | An aqueous preparation of a transgenic protein structure that includes an FC domain |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5580856A (en) | 1994-07-15 | 1996-12-03 | Prestrelski; Steven J. | Formulation of a reconstituted protein, and method and kit for the production thereof |
EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
US7294481B1 (en) | 1999-01-05 | 2007-11-13 | Immunex Corporation | Method for producing recombinant proteins |
US20010021380A1 (en) | 1999-04-19 | 2001-09-13 | Pluenneke John D. | Soluble tumor necrosis factor receptor treatment of medical disorders |
WO2000062790A2 (en) | 1999-04-19 | 2000-10-26 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
US20040220103A1 (en) | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
BR0108193A (pt) | 2000-02-10 | 2003-02-25 | Wyeth Corp | Processo para tratamento ou inibição de dano celular ou morte celular |
PT1441589E (pt) * | 2001-11-08 | 2012-08-13 | Abbott Biotherapeutics Corp | Formulação farmacêutica líquida estável de anticorpos igg |
JP4583762B2 (ja) | 2002-02-27 | 2010-11-17 | イミュネックス・コーポレーション | ポリペプチド製剤 |
BRPI0407649A (pt) | 2003-02-28 | 2006-02-21 | Ares Trading Sa | formulação lìquida de proteìnas de ligação do fator de necrose tumoral, processo de preparação de formulação lìquida de proteìnas de ligação do fator de necrose tumoral e forma de apresentação de formulação |
WO2004082715A1 (ja) * | 2003-03-20 | 2004-09-30 | Eisai Co., Ltd. | 炎症性腸疾患治療剤としての併用医薬 |
CN100509847C (zh) | 2003-08-01 | 2009-07-08 | 安美基公司 | 结晶肿瘤坏死因子受体2多肽 |
RS20060259A (en) * | 2003-10-14 | 2008-08-07 | Intermune Inc., | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication |
WO2005082377A1 (ja) | 2004-03-01 | 2005-09-09 | Ajinomoto Co., Inc. | 抗ヒトTNF-α抗体活性低下抑制剤 |
US8206981B2 (en) | 2004-03-05 | 2012-06-26 | Dsm Ip Assets B.V. | Process for cell culturing by continuous perfusion and alternating tangential flow |
US20060008415A1 (en) * | 2004-06-25 | 2006-01-12 | Protein Design Labs, Inc. | Stable liquid and lyophilized formulation of proteins |
US20070196364A1 (en) | 2004-07-27 | 2007-08-23 | Human Genome Sciences, Inc. | Pharmaceutical Formulation and Process |
US7300773B2 (en) | 2004-08-27 | 2007-11-27 | Wyeth Research Ireland Limited | Production of TNFR-Ig |
JP5068167B2 (ja) | 2005-06-10 | 2012-11-07 | 中外製薬株式会社 | メグルミンを含有するタンパク質製剤の安定化剤、およびその利用 |
AR058567A1 (es) * | 2005-12-20 | 2008-02-13 | Bristol Myers Squibb Co | Formulaciones de proteinas estables |
JP5405122B2 (ja) | 2005-12-21 | 2014-02-05 | ワイス・エルエルシー | 低粘度のタンパク質製剤およびその用途 |
CA2646508A1 (en) | 2006-03-17 | 2007-09-27 | Biogen Idec Ma Inc. | Stabilized polypeptide compositions |
EP2021030A2 (en) | 2006-04-21 | 2009-02-11 | Amgen, Inc. | Buffering agents for biopharmaceutical formulations |
EP2081553B1 (en) | 2006-10-06 | 2020-08-12 | Amgen Inc. | Stable antibody formulations |
EP2094247B1 (en) * | 2006-10-20 | 2022-06-29 | Amgen Inc. | Stable polypeptide formulations |
MX2009004519A (es) | 2006-11-03 | 2009-05-12 | Wyeth Corp | Sustancias que inhiben la glucolisis en un cultivo de celulas. |
CA2790018C (en) | 2006-12-21 | 2015-02-03 | Amgen Inc. | Formulations |
KR20090127326A (ko) | 2007-03-02 | 2009-12-10 | 와이어쓰 | 폴리펩티드의 생산을 위한 세포 배양물 중에서 구리 및 글루타메이트의 용도 |
EP2014760A1 (en) | 2007-06-13 | 2009-01-14 | CMC Biopharmaceuticals A/S | A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process |
CN103977404A (zh) | 2007-06-14 | 2014-08-13 | 比奥根艾迪克Ma公司 | 抗体制剂 |
CA2707483A1 (en) * | 2007-11-30 | 2009-06-11 | Wolfgang Fraunhofer | Protein formulations and methods of making same |
CN103720587A (zh) * | 2008-02-07 | 2014-04-16 | 安姆根有限公司 | 稳定化的蛋白组合物 |
EP2260054B1 (en) | 2008-02-29 | 2015-06-03 | Biogen Idec MA Inc. | Purified immunoglobulin fusion proteins and methods of their purification |
BRPI0917888A2 (pt) * | 2008-09-19 | 2014-02-25 | Pfizer | Formulação de anticorpo líquida estável |
WO2011015926A1 (en) | 2009-08-03 | 2011-02-10 | Avesthagen Limited | A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein |
HUE048980T2 (hu) | 2009-08-11 | 2020-08-28 | Hoffmann La Roche | Fehérjék elõállítása glutaminmentes sejttenyésztõ táptalajban |
EP2490780A4 (en) | 2009-10-20 | 2014-04-09 | Merck Sharp & Dohme | USE OF MIXED MODE CHROMATOGRAPHY FOR CAPTURE AND PURIFICATION OF BASIC ANTIBODY PRODUCTS |
EP2516467A2 (en) | 2009-12-23 | 2012-10-31 | Emergent Product Development Seattle, LLC | Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof |
WO2011134920A1 (en) | 2010-04-26 | 2011-11-03 | Novartis Ag | Improved cell culture medium |
CN102946858B (zh) * | 2010-05-10 | 2015-09-30 | 英塔斯制药有限公司 | 含有免疫球蛋白Fc的多肽的液体制剂 |
US20130209465A1 (en) | 2010-07-30 | 2013-08-15 | Arecor Ltd. | Stabilized Aqueous Antibody Compositions |
WO2012023085A1 (en) | 2010-08-20 | 2012-02-23 | Wyeth Llc | Cell culture of growth factor-free adapted cells |
JP2012049074A (ja) | 2010-08-30 | 2012-03-08 | Makita Corp | 電動工具のバッテリパック |
JP2013536683A (ja) | 2010-08-31 | 2013-09-26 | フリエスランド ブランズ ビー.ブイ. | 真核細胞のための培養培地 |
JP5996631B2 (ja) | 2011-04-20 | 2016-09-21 | サンド・アクチエンゲゼルシヤフト | TNFR:Fc融合タンパク質の安定した医薬液剤 |
UY34105A (es) * | 2011-06-03 | 2012-07-31 | Lg Life Sciences Ltd | Formulación líquida estable de etanercept |
KR102061355B1 (ko) * | 2011-07-01 | 2019-12-31 | 바이오젠 엠에이 인코포레이티드 | 아르기닌-없는 tnfr : fc-융합 폴리펩티드 조성물 및 이용 방법 |
KR102108663B1 (ko) | 2011-07-01 | 2020-05-07 | 암젠 인크 | 포유동물 세포 배양 |
JP6220789B2 (ja) * | 2011-10-18 | 2017-10-25 | コヒラス・バイオサイエンシズ・インコーポレイテッド | 糖およびポリオールの組合せによって安定化されたエタネルセプト製剤 |
-
2013
- 2013-07-09 BR BR112015000203A patent/BR112015000203A2/pt not_active IP Right Cessation
- 2013-07-09 EP EP13817186.3A patent/EP2869817A4/en not_active Withdrawn
- 2013-07-09 EP EP13816429.8A patent/EP2869816A4/en not_active Withdrawn
- 2013-07-09 IN IN5KON2015 patent/IN2015KN00005A/en unknown
- 2013-07-09 CN CN201380046666.4A patent/CN104661651A/zh active Pending
- 2013-07-09 EA EA201590161A patent/EA029193B1/ru not_active IP Right Cessation
- 2013-07-09 SG SG11201500138VA patent/SG11201500138VA/en unknown
- 2013-07-09 PE PE2015000026A patent/PE20150762A1/es not_active Application Discontinuation
- 2013-07-09 AU AU2013290289A patent/AU2013290289B2/en not_active Expired - Fee Related
- 2013-07-09 WO PCT/US2013/049778 patent/WO2014011672A1/en active Application Filing
- 2013-07-09 JP JP2015521752A patent/JP6271536B2/ja active Active
- 2013-07-09 CA CA2878508A patent/CA2878508A1/en not_active Abandoned
- 2013-07-09 BR BR112015000229A patent/BR112015000229A2/pt not_active IP Right Cessation
- 2013-07-09 WO PCT/US2013/049716 patent/WO2014011629A1/en active Application Filing
- 2013-07-09 MX MX2015000337A patent/MX2015000337A/es unknown
- 2013-07-09 JP JP2015521742A patent/JP2015525762A/ja active Pending
- 2013-07-09 KR KR1020157000510A patent/KR20150030704A/ko not_active Application Discontinuation
-
2014
- 2014-12-31 IL IL236527A patent/IL236527A0/en unknown
-
2015
- 2015-01-08 US US14/592,654 patent/US9662396B2/en active Active
- 2015-01-08 CL CL2015000051A patent/CL2015000051A1/es unknown
- 2015-01-08 US US14/592,569 patent/US10822429B2/en active Active
- 2015-01-09 DO DO2015000006A patent/DOP2015000006A/es unknown
- 2015-02-09 EC ECIEPI20154752A patent/ECSP15004752A/es unknown
- 2015-10-15 HK HK15110120.5A patent/HK1213174A1/zh unknown
- 2015-10-15 HK HK15110117.0A patent/HK1209343A1/xx unknown
-
2020
- 2020-09-28 US US17/034,134 patent/US20210007991A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2869817A1 (en) | 2015-05-13 |
AU2013290289A1 (en) | 2015-01-29 |
DOP2015000006A (es) | 2015-05-31 |
EA201590161A1 (ru) | 2015-07-30 |
BR112015000203A2 (pt) | 2017-06-27 |
EP2869816A1 (en) | 2015-05-13 |
US9662396B2 (en) | 2017-05-30 |
JP2015525762A (ja) | 2015-09-07 |
IL236527A0 (en) | 2015-02-26 |
HK1209343A1 (en) | 2016-04-01 |
EP2869817A4 (en) | 2016-04-06 |
WO2014011672A1 (en) | 2014-01-16 |
EA029193B1 (ru) | 2018-02-28 |
PE20150762A1 (es) | 2015-06-20 |
SG11201500138VA (en) | 2015-03-30 |
US20150196645A1 (en) | 2015-07-16 |
CA2878508A1 (en) | 2014-01-16 |
KR20150030704A (ko) | 2015-03-20 |
AU2013290289B2 (en) | 2018-03-29 |
CN104661651A (zh) | 2015-05-27 |
WO2014011629A1 (en) | 2014-01-16 |
JP2015525763A (ja) | 2015-09-07 |
ECSP15004752A (es) | 2015-12-31 |
US10822429B2 (en) | 2020-11-03 |
US20150125532A1 (en) | 2015-05-07 |
CL2015000051A1 (es) | 2015-07-31 |
MX2015000337A (es) | 2015-09-25 |
IN2015KN00005A (pt) | 2015-07-31 |
US20210007991A1 (en) | 2021-01-14 |
JP6271536B2 (ja) | 2018-01-31 |
HK1213174A1 (zh) | 2016-06-30 |
EP2869816A4 (en) | 2016-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015000229A2 (pt) | formulações aquosas estáveis de etanercept | |
BR112014009087A2 (pt) | formulações de etanercept estabilizadas com xilitol | |
CY1122853T1 (el) | Σταθερα σκευασματα λινακλοτιδης | |
BR112015004984A2 (pt) | formulações aquosas estáveis de adalimumab | |
EA201692301A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
MX2015008628A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
CY1116987T1 (el) | Συμπυκνωμενα ιμιδαζολυλιμιδαζολια ως αντιϊικες ενωσεις | |
MX2015008627A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
BR112015021983A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
MX2016015093A (es) | Derivados de acido boronico y sus usos terapeuticos. | |
EA201691216A1 (ru) | Композиции линаклотида с замедленным высвобождением | |
EA201500298A1 (ru) | Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы | |
MX340147B (es) | Composiciones farmacéuticas y nutracéuticas del ácido abscísico. | |
MX2016001422A (es) | Composicion farmaceutica de fingolimod. | |
AR090975A1 (es) | N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxihexil)amino)-2-oxo-n-fenil-1,2-dihidroquinolina-3-carboxamida | |
AR090073A1 (es) | N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos | |
EA201600394A1 (ru) | Трициклические соединения пиперидина | |
MX2015000179A (es) | Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas. | |
MX2019012375A (es) | Formulaciones del inhibidor del antigeno-1 asociado a la funcion de linfocitos (lfa-1). | |
PH12015502717A1 (en) | Anti-fibrogenic compounds, methods and uses thereof | |
EA201492280A1 (ru) | Стабильный состав пексиганана | |
EA201400444A1 (ru) | Производные 2-оксопиперидинила | |
EA201500446A1 (ru) | Фармацевтическая композиция для снижения уровня n-оксида триметиламина | |
IN2013MU02442A (pt) | ||
EA201590886A1 (ru) | Замещенные производные индола |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2522 DE 07-05-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |